A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of non-systemic intranasal product candidates called pherines. Our broad and diverse neuroscience pipeline currently consists of five clinical-stage pherine product candidates, each with a novel mechanism of action (MOA) and positive clinical data in their targeted indication(s). Pherines specifically and selectively bind to peripheral receptors in human nasal chemosensory neurons, and are designed to rapidly activate nose-to-brain neurocircuits believed to regulate brain areas without requiring systemic absorption or uptake into the brain to achieve desired therapeutic benefits. Our most advanced intranasal pherine product candidate is fasedienol, which is being investigated in our U.S. registration-directed PALISADE Program for the acute treatment of social anxiety disorder (SAD).
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 789K | - | - | - | - | - |
| Net Income | -67M | -51M | -29M | -59M | -49M | -42M |
| EPS | $-1.90 | $-1.67 | $-1.52 | $-8.51 | $-7.38 | $-14.70 |
| Free Cash Flow | -60M | -42M | -26M | -50M | -45M | -12M |
| ROIC | -84.9% | -73.0% | -25.7% | -222.0% | -75.3% | -46.0% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.01 | 0.20 | 0.08 | 0.02 | 0.00 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -70M | -56M | -33M | -59M | -48M | -18M |
| Operating Margin | -8859.8% | - | - | - | - | - |
| ROE | -131.7% | -55.7% | -25.7% | -490.5% | -75.3% | -46.0% |
| Shares Outstanding | 40M | 31M | 19M | 27M | 7M | 7M |
Vistagen Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Vistagen Therapeutics, Inc. (VTGN) has a 5-year average return on invested capital (ROIC) of -55.0%. This is below average and may indicate limited pricing power.
Vistagen Therapeutics, Inc. (VTGN) has a market capitalization of $23M. It is classified as a small-cap stock.
Vistagen Therapeutics, Inc. (VTGN) does not currently pay a regular dividend.
Vistagen Therapeutics, Inc. (VTGN) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Vistagen Therapeutics, Inc. (VTGN) generated $-42 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Vistagen Therapeutics, Inc. (VTGN) has a debt-to-equity ratio of 0.20. This indicates a conservatively financed balance sheet.
Vistagen Therapeutics, Inc. (VTGN) reported earnings per share (EPS) of $-1.67 in its most recent fiscal year.
Vistagen Therapeutics, Inc. (VTGN) has a return on equity (ROE) of -55.7%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 14 years of financial data for Vistagen Therapeutics, Inc. (VTGN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Vistagen Therapeutics, Inc. (VTGN) has a book value per share of $2.29, based on its most recent annual SEC filing.